Cloud Services & Network Solutions
Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. How an Unproven Alzheimer’s Drug Got Approved Source: NY Times Tech
